Gland Pharma IPO Details

Gland Pharma IPOGland Pharma IPO description – Gland Pharma is one of the fastest growing generic injectables-focused companies, selling its products primarily under a business to business (B2B) model in over 60 countries including the United States, Europe, Canada, Australia, India and the Rest of the world. The company was established in Hyderabad, India in 1978 and has expanded from liquid parenterals to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops. Gland Pharma has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities. As of March 31, 2020, it had manufacturing capacity for finished formulations of approximately 755 million units per annum. As of March 31, 2020, the company and its partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval. The 265 ANDA filings comprise 189 ANDA filings for sterile injectables, 50 for oncology and 26 for ophthalmics related products. 

Promoters of Gland Pharma – Fosun Pharma Industrial PTE Ltd and Shanghai Fosun Pharmaceutical (Group) Co Ltd
Gland Pharma IPO details
Subscription Dates 9 – 11 November 2020
Price Band INR1,490 – 1,500 per share 
Fresh issue INR1,250 crore
Offer For Sale 34,863,635 shares (INR5,194.68 – 5,229.55 crore)
Total IPO size 34,863,635 shares (INR6,444.68 – 6,479.55 crore)
Minimum bid (lot size) 10 shares
Face Value  INR1 per share
Retail Allocation 35%
Listing On NSE, BSE

Gland Pharma’s financial performance (in INR crore)

  FY2018 FY2019 FY2020 Q1 FY2021
Revenue 1,671.7 2,129.8 2,772.4 916.3
Expenses 1,170.2 1,423.5 1,779.5 496.3
Net income 320.5 451.6 767.6 312.6
Net margin (%) 19.2 21.2 27.7 34.1

More about Gland Pharma IPO

Registrar of Gland Pharma IPO

Link Intime India Private Limited
C-101, 1st Floor, 247 Park Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai – 400 083
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email: [email protected]

Gland Pharma Contact Details

Gland Pharma Limited
Sy. No. 143 – 148, 150 and 151,
Near Gandi Maisamma ‘X’ Roads,
D.P. Pally, Dundigal,
Dundigal – Gandi Maisamma (M),
Medchal-Malkajgiri District,
Hyderabad 500 043
Phone: +91 40 3051 0999
Email: [email protected]

Valuation of Gland Pharma (as of FY2020)

Earnings Per Share (EPS): INR49.88 
Price/Earnings (PE ratio): 29.87 – 30.07
Return on Net Worth (RONW): 21.2%
Net Asset Value (NAV): INR235.32 per share

Gland Pharma IPO Subscription Details

Category Shares offered Subscription (no. of times, at 5 PM)
Day 1 Day 2 Day 3
QIB 86,39,394 0.00 0.48 6.39
NII 64,79,546 0.01 0.03 0.50
Retail 1,51,18,939 0.08 0.15 0.23
Total 3,02,37,879 0.04 0.22 2.05

Gland Pharma IPO Analyst Reviews

BP Wealth – Subscribe
Choice Broking – Subscribe with caution
Geojit Financial Services – Subscribe
GEPL Capital – Subscribe
ICICIdirect – Subscribe
KR Choksey – Subscribe
Samco Securities – Subscribe for long term
Sharekhan – Subscribe
SMC Global – 3/5

Gland Pharma IPO Allotment Status

Gland Pharma IPO allotment status is now available on Link Intime’s website. Click on this link to get allotment status.

Listing Performance of Gland Pharma

IPO Opening Date: 9 November 2020
IPO Closing Date: 11 November 2020
Finalisation of Basis of Allotment: 17 November 2020
Initiation of refunds: 18 November 2020
Transfer of shares to demat accounts: 19 November 2020
Listing Date: 20 November 2020
Opening Price on NSE: INR1,710 per share (up 14% from IPO price) 
Closing Price on NSE: INR1,819.55 per share (up 21.3% from IPO price)


Please enter your comment!
Please enter your name here

Free IPO Investing With India's Leading Broker